1e
19
1
49
2
2
18
1b
1d
18
31
5d
1d
2 29
1d
25
Paula M Oliver, PhD
78
5d
Associate Professor of Pathology and Laboratory Medicine
28
55
3
78
Member, Abramson Cancer Center
57
Member, Institute for Immunology
6f
Associate Professor, Children's Hospital of Philadelphia
77
Director, Protective Immunity and Immunopathology Affinity Group
88
Co-Director, Division of Protective Immunity, Children's Hospital of Philadelphia
83
Director, CHOP Research Institute Cores, Children's Hospital of Philadelphia
11
Department: Pathology and Laboratory Medicine
4
1
23
1f
Graduate Group Affiliations
8
b
-
5c
- Immunology 6b
- Cell and Molecular Biology e
1d
46
Contact information
53
4
3
3
3
2
29
4
b
1f
53
Protective Immunity Division 816F/ARC
30 Children’s Hospital of Philadelphia
29 The University of Pennsylvania
46 3615 Civic Center Blvd. 816F/ARC
Philadelphia, PA 19104
26
30 Children’s Hospital of Philadelphia
29 The University of Pennsylvania
46 3615 Civic Center Blvd. 816F/ARC
Philadelphia, PA 19104
2e
Office: 267-426-2839
32 Fax: 267-426-5165
24
93
32 Fax: 267-426-5165
24
Email:
paulao@mail.med.upenn.edu
12
paulao@mail.med.upenn.edu
13
Education:
21 7 BS 14 (Zoology) c
38 North Carolina State University, 1989.
21 8 PhD 16 (Pathology) c
44 University of North Carolina at Chapel Hill, 1998.
c
3
3
3
3
8d
Permanent link21 7 BS 14 (Zoology) c
38 North Carolina State University, 1989.
21 8 PhD 16 (Pathology) c
44 University of North Carolina at Chapel Hill, 1998.
c
2 29
21
1e
1d
24
5e
10c Our focus is on defining new mechanisms that regulate immune cell activation and protective immune responses. Our goal is to use this information to design therapies with which to treat the immune-mediated pathologies found in autoimmune and allergic disease.
8
18 Research Summary
416 During pathogenic infection, immune cells collaborate to remove invading organisms while minimizing collateral damage. Immune cells must continually respond to external stimuli, and adjust their levels of key regulatory proteins, to transition between poised and active states. To accomplish this, immune cells can increase protein production, modify existing proteins, or change their rate of protein degradation. ‘Tagging’ a protein with ubiquitin is a post-translational modification that can improve interactions between proteins to promote signaling, or initiate protein degradation. Ubiquitylation is regulated by enzymes that add (E3 ubiquitin ligases) or subtract (deubiquitylating enzymes) ubiquitin from substrates. We use systems biology approaches to define changes in ubiquitylation as activation states change, and to identify ubiquitin ligases that regulate immune cell fate. We combine this information with genetic, cellular and biochemical approaches to define how ubiquitin enzymes regulate immune cell biology.
8
384 One area of focus in the lab has centered on catalytic HECT-type E3 ubiquitin ligases of the Nedd4-family. The 9 members of this family that exist in mammalian cells evolved from a common yeast progenitor known as RSP5. We have identified a small family of membrane tethered adaptors, Ndfip1 and Ndfip2, that activate several Nedd4-family E3s. Additionally, we have determined that these adaptors regulate T cell activation, CD4 differentiation and effector function, and Treg cell metabolism and lineage stability. We combined this information on biologic function with biochemical data in which we defined precisely how these adaptors activate the enzymatic activity of Nedd4-family ligases, and are now using this information in the rational design of therapeutics. Based on our data, such therapeutics will be particularly useful in the treatment of autoimmune and/or allergic disease.
8
2b2 Our recent work has employed systems biology approaches in which we intrgrated transcriptome, proteome and ubiquitome information to identify Cullin E3 ubiquitin ligases that are particularly active as T cells transition from resting to activated states. We are now generating genetic models in which to test the the biologic relevance of these ligases in protective immune responses. We are now poised to define how cullin ligases form distinct ubiquitin complexes in T cells or other immune cells, and the unique set of substrates targeted by these complexes. Once we answer these questions we will be positioned to translate this information into new therapies for patients.
8
8
15 Lab Personnel
8
2f Emily Moser PhD – Postdoctoral Fellow
2b Awo Layman – MD/PhD Student (IGG)
2e Natania Field – MD/PhD Student (MVP)
2d Asif Dar PhD – Postdoctoral Fellow
30 Joseph Dybas PhD – Postdoctoral Fellow
23 Yan Chen PhD – Technician
25 Keisuke Sawada – Technician
27 Jennifer Roof – Undergraduate
24 Varshini Gali - Undergraduate
26 29
27
Description of Research Expertise
22 Research Interest10c Our focus is on defining new mechanisms that regulate immune cell activation and protective immune responses. Our goal is to use this information to design therapies with which to treat the immune-mediated pathologies found in autoimmune and allergic disease.
8
18 Research Summary
416 During pathogenic infection, immune cells collaborate to remove invading organisms while minimizing collateral damage. Immune cells must continually respond to external stimuli, and adjust their levels of key regulatory proteins, to transition between poised and active states. To accomplish this, immune cells can increase protein production, modify existing proteins, or change their rate of protein degradation. ‘Tagging’ a protein with ubiquitin is a post-translational modification that can improve interactions between proteins to promote signaling, or initiate protein degradation. Ubiquitylation is regulated by enzymes that add (E3 ubiquitin ligases) or subtract (deubiquitylating enzymes) ubiquitin from substrates. We use systems biology approaches to define changes in ubiquitylation as activation states change, and to identify ubiquitin ligases that regulate immune cell fate. We combine this information with genetic, cellular and biochemical approaches to define how ubiquitin enzymes regulate immune cell biology.
8
384 One area of focus in the lab has centered on catalytic HECT-type E3 ubiquitin ligases of the Nedd4-family. The 9 members of this family that exist in mammalian cells evolved from a common yeast progenitor known as RSP5. We have identified a small family of membrane tethered adaptors, Ndfip1 and Ndfip2, that activate several Nedd4-family E3s. Additionally, we have determined that these adaptors regulate T cell activation, CD4 differentiation and effector function, and Treg cell metabolism and lineage stability. We combined this information on biologic function with biochemical data in which we defined precisely how these adaptors activate the enzymatic activity of Nedd4-family ligases, and are now using this information in the rational design of therapeutics. Based on our data, such therapeutics will be particularly useful in the treatment of autoimmune and/or allergic disease.
8
2b2 Our recent work has employed systems biology approaches in which we intrgrated transcriptome, proteome and ubiquitome information to identify Cullin E3 ubiquitin ligases that are particularly active as T cells transition from resting to activated states. We are now generating genetic models in which to test the the biologic relevance of these ligases in protective immune responses. We are now poised to define how cullin ligases form distinct ubiquitin complexes in T cells or other immune cells, and the unique set of substrates targeted by these complexes. Once we answer these questions we will be positioned to translate this information into new therapies for patients.
8
8
15 Lab Personnel
8
2f Emily Moser PhD – Postdoctoral Fellow
2b Awo Layman – MD/PhD Student (IGG)
2e Natania Field – MD/PhD Student (MVP)
2d Asif Dar PhD – Postdoctoral Fellow
30 Joseph Dybas PhD – Postdoctoral Fellow
23 Yan Chen PhD – Technician
25 Keisuke Sawada – Technician
27 Jennifer Roof – Undergraduate
24 Varshini Gali - Undergraduate
26 29
23
92 Joseph M. Dybas, Claire E. O’Leary, Hua Ding, Lynn A. Spruce, Steve H. Seeholzer and Paula M. Oliver ad : Integrative proteomics reveals that CD4+ T cell activation promotes non-degradative ubiquitylation. Nature Immunology 20(6): 747, June 2019.
ca Emily Moser and Paula M. Oliver: Regulation of Autoimmune Disease by the E3 Ubiquitin Ligase Itch. Cellular Immunology June 2019.
125 Emily K Moser, Natania S Field and Paula M Oliver: Aberrant Th2 inflammation drives dysfunction of alveolar macrophages and susceptibility to bacterial pneumonia. Cellular & Molecular Immunology 15(5): 480-492, May 2018.
14e Awo Akosua K. Layman, Guoping Deng, Claire E. O’Leary, Samuel Tadros, Rajan M. Thomas, Joseph M. Dybas, Emily K. Moser, Andrew D. Wells, Nicolai M. Doliba & Paula M. Oliver: Ndfip1 restricts mTORC1 signaling and glycolysis in regulatory T cells to prevent autoinflammatory disease. 43 Nature Communications 8: 15677, June 2017.
11b Awo AK Layman, Stephanie Sprout, Dylan Phillips, and Paula M Oliver.: Ndfip1 restricts Th17 cell potency by limiting lineage stability and proinflammatory cytokine production. Sci Reports 4(7): 39649, Jan 2017.
e4 Awo Layman and Paula Oliver: Ubiquitin ligases and Dubs in CD4+ T cell effector fate choice and function. Journal of Immunology 196(10): 3975-82, May 2016.
171 Claire E. O'Leary, Christopher Riling, Lynn Spruce, Hua Ding, Suresh Kumar, Guoping Deng, Yuhong Liu, Steven H. Seeholzer, and Paula M. Oliver: Ndfip-mediated degradation of Jak1 tunes cytokine signaling to limit expansion of CD4+ effector T cells. Nature Communications 18(7): 11226, April 2016.
180 Christopher Riling, Hari Kamadurai, Suresh Kumar, Claire E. O’Leary, Kuen-Phon Wu, Erica E. Manion, Mingjie Ying, Brenda A. Schulmanb, and Paula M. Oliver: Itch WW domains inhibit its E3 ubiquitin ligase activity by blocking E2-E3 transthiolation. Journal of Biological Chemistry 290(39): 23875-87, Sept 2015.
15a Allison M. Beal, Natalia Ramos-Hernandez, Chris R. Riling, Erin A. Nowelsky and Paula M. Oliver: TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentation. Nature Immunology 13(1): 77-85, January 2012 PMCID: PMC3542978.
2c
7
1d
1f
Selected Publications
13a Emily Moser, Jennifer Roof, Joseph Dybas, Lynn Spruce, Steve Seeholzer, Michael Cancro, and Paula Oliver.: The E3 ubiquitin ligase Itch restricts antigen-driven B cell responses. Journal of Experimental Medicine 216(9): 2170, September 2019.92 Joseph M. Dybas, Claire E. O’Leary, Hua Ding, Lynn A. Spruce, Steve H. Seeholzer and Paula M. Oliver ad : Integrative proteomics reveals that CD4+ T cell activation promotes non-degradative ubiquitylation. Nature Immunology 20(6): 747, June 2019.
ca Emily Moser and Paula M. Oliver: Regulation of Autoimmune Disease by the E3 Ubiquitin Ligase Itch. Cellular Immunology June 2019.
125 Emily K Moser, Natania S Field and Paula M Oliver: Aberrant Th2 inflammation drives dysfunction of alveolar macrophages and susceptibility to bacterial pneumonia. Cellular & Molecular Immunology 15(5): 480-492, May 2018.
14e Awo Akosua K. Layman, Guoping Deng, Claire E. O’Leary, Samuel Tadros, Rajan M. Thomas, Joseph M. Dybas, Emily K. Moser, Andrew D. Wells, Nicolai M. Doliba & Paula M. Oliver: Ndfip1 restricts mTORC1 signaling and glycolysis in regulatory T cells to prevent autoinflammatory disease. 43 Nature Communications 8: 15677, June 2017.
11b Awo AK Layman, Stephanie Sprout, Dylan Phillips, and Paula M Oliver.: Ndfip1 restricts Th17 cell potency by limiting lineage stability and proinflammatory cytokine production. Sci Reports 4(7): 39649, Jan 2017.
e4 Awo Layman and Paula Oliver: Ubiquitin ligases and Dubs in CD4+ T cell effector fate choice and function. Journal of Immunology 196(10): 3975-82, May 2016.
171 Claire E. O'Leary, Christopher Riling, Lynn Spruce, Hua Ding, Suresh Kumar, Guoping Deng, Yuhong Liu, Steven H. Seeholzer, and Paula M. Oliver: Ndfip-mediated degradation of Jak1 tunes cytokine signaling to limit expansion of CD4+ effector T cells. Nature Communications 18(7): 11226, April 2016.
180 Christopher Riling, Hari Kamadurai, Suresh Kumar, Claire E. O’Leary, Kuen-Phon Wu, Erica E. Manion, Mingjie Ying, Brenda A. Schulmanb, and Paula M. Oliver: Itch WW domains inhibit its E3 ubiquitin ligase activity by blocking E2-E3 transthiolation. Journal of Biological Chemistry 290(39): 23875-87, Sept 2015.
15a Allison M. Beal, Natalia Ramos-Hernandez, Chris R. Riling, Erin A. Nowelsky and Paula M. Oliver: TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentation. Nature Immunology 13(1): 77-85, January 2012 PMCID: PMC3542978.
2c